1. Keks N, Schwartz D, Hope J. Stopping and switching antipsychotic drugs. Aust Prescr. 2019;42(5):152-157. doi:10.18773/austprescr.2019.052 [cited 2022 July 22]
2. Li M. Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms. J Psychopharmacol. 2016 Aug;30(8):749-70. doi: 10.1177/0269881116654697. Epub 2016 Jul 1. PMID: 27371498; PMCID: PMC4944179. [cited 2022 July 22]
3. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L [corrected to Matalon L]. “Depot antipsychotic drugs. Place in therapy.” Drugs. 1994 May;47(5):741-73. doi: 10.2165/00003495-199447050-00004. Erratum in: Drugs 1994 Oct;48(4):616. PMID: 7520856. [cited 2022 July 22]
4. Harrow M, Jobe T, ” Long-term antipsychotic treatment of schizophrenia – does it help or hurt over a 20-year period?” Journal of World Psychiatry 2018 Jun, PMID 29856562 [cited 2022 July 22]
5. Correll et al., “What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?” Journal or World Psychiatry 2018 May [cited 2022 July 22]
6. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27(11):2979-2986. doi:10.1523/JNEUROSCI.5416-06.2007. [cited 2022 July 22]
7. Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. Ther Adv Psychopharmacol. 2020;10:2045125320937910. Published 2020 Jul 6. doi:10.1177/2045125320937910. [cited 2022 July 22]
8. WALKER, TOM. “ULYSSES CONTRACTS IN MEDICINE.” Law and Philosophy, vol. 31, no. 1, 2012, pp. 77–98. JSTOR, www.jstor.org/stable/41348267. [cited 2022 July 22]
9. Cooper RE, Hanratty É, Morant N, Moncrieff J (2019) Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation. PLoS ONE 14(6): e0218711. https://doi.org/10.1371/journal.pone.0218711 [cited 2022 July 22]
10. Hedges DW, Woon FL, Hoopes SP. Caffeine-induced psychosis. CNS Spectr. 2009 Mar;14(3):127-9. doi: 10.1017/s1092852900020101. PMID: 19407709. [cited 2022 July 22]
11. Wang HR, Woo YS, Bahk WM. Caffeine-induced psychiatric manifestations: a review. Int Clin Psychopharmacol. 2015 Jul;30(4):179-82. doi: 10.1097/YIC.0000000000000076. PMID: 25856116. [cited 2022 July 22]
12. NIDA. 2020, May 28. Is there a link between marijuana use and psychiatric disorders? [cited 2022 July 22]
13. Sahoo S, Mehra A, Grover S. Acute Hyperglycemia Associated with Psychotic Symptoms in a Patient with Type 1 Diabetes Mellitus: A Case Report. Innov Clin Neurosci. 2016;13(11-12):25-27. Published 2016 Dec 1. [cited 2022 July 22]
14. Herbert C, Meixner F, Wiebking C, Gilg V. Regular Physical Activity, Short-Term Exercise, Mental Health, and Well-Being Among University Students: The Results of an Online and a Laboratory Study. Front Psychol. 2020;11:509. Published 2020 May 26. doi:10.3389/fpsyg.2020.00509 [cited 2022 July 22]
15. Segura-Aguilar J., Paris I. (2014) Mechanisms of Dopamine Oxidation and Parkinson’s Disease. In: Kostrzewa R. (eds) Handbook of Neurotoxicity. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5836-4_16 [cited 2022 July 22]
16. Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013 Dec;27(12):1021-48. doi: 10.1007/s40263-013-0114-6. PMID: 24170642.[cited 2022 July 22]
17. Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997 Dec;33(6):454-71. doi: 10.2165/00003088-199733060-00004. PMID: 9435993.[cited 2022 July 22]
18. Gardos G, Cole JO, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry. 1978 Nov;135(11):1321-4. doi: 10.1176/ajp.135.11.1321. PMID: 30287.[cited 2022 July 22]
19. Tranter R, Healy D. Neuroleptic discontinuation syndromes. J Psychopharmacol. 1998;12(4):401-6. doi: 10.1177/026988119801200412. PMID: 10065916. [cited 2022 July 22]
20. Fink EB. Unexpected and prolonged akinesia: a case report. J Clin Psychiatry. 1978 Nov;39(11):817-8. PMID: 31353. [cited 2022 July 22]
21. Hormone Health Network Non-Diabetic Hypoglycemia EDITOR(S): Prof. Margaret Eckert-Norton, PHD, FNP-BC, CDE, Ramon Martinez, M.D., Susan Kirk, M.D. LAST UPDATED: July 2020. [cited 2022 July 22]
22. FDA label LATUDA (lurasidone hydrochloride) Approved 2010 Revised 2013 [cited 2022 July 22]
23. Barnes SS, Badre N. Is the Evidence Strong Enough to Warrant Long-Term Antipsychotic Use in Compulsory Outpatient Treatment? Psychiatr Serv. 2016 Jul 1;67(7):784-6. doi: 10.1176/appi.ps.201500408. Epub 2016 Mar 15. PMID: 26975525. [cited 2022 July 22]
24. Ostrow L, Jessell L, Hurd M, Darrow SM, Cohen D. Discontinuing Psychiatric Medications: A Survey of Long-Term Users. Psychiatr Serv. 2017 Dec 1;68(12):1232-1238. doi: 10.1176/appi.ps.201700070. Epub 2017 Jul 17. PMID: 28712356. [cited 2022 July 22]
25. Salomon C, Hamilton B. “All roads lead to medication?” Qualitative responses from an Australian first-person survey of antipsychotic discontinuation. Psychiatr Rehabil J. 2013 Sep;36(3):160-5. doi: 10.1037/prj0000001. Epub 2013 Jul 1. PMID: 23815172. [cited 2022 July 22]
26. Behan C. The benefits of meditation and mindfulness practices during times of crisis such as COVID-19. Ir J Psychol Med. 2020 Dec;37(4):256-258. doi: 10.1017/ipm.2020.38. Epub 2020 May 14. PMID: 32406348; PMCID: PMC7287297. [cited 2022 July 22]
27. Meister K, Becker S. Yoga bei psychischen Störungen [Yoga for mental disorders]. Nervenarzt. 2018 Sep;89(9):994-998. German. doi: 10.1007/s00115-018-0537-x. PMID: 29858642. [cited 2022 July 22]
28. Antonelli M, Barbieri G, Donelli D. Effects of forest bathing (shinrin-yoku) on levels of cortisol as a stress biomarker: a systematic review and meta-analysis. Int J Biometeorol. 2019 Aug;63(8):1117-1134. doi: 10.1007/s00484-019-01717-x. Epub 2019 Apr 18. PMID: 31001682. [cited 2022 July 22]
29. Raglan GB, Swanson LM, Arnedt JT. Cognitive Behavioral Therapy for Insomnia in Patients with Medical and Psychiatric Comorbidities. Sleep Med Clin. 2019 Jun;14(2):167-175. doi: 10.1016/j.jsmc.2019.01.001. Epub 2019 Mar 29. PMID: 31029184. [cited 2022 July 22]
30. Schuch FB, Vancampfort D. Physical activity, exercise, and mental disorders: it is time to move on. Trends Psychiatry Psychother. 2021 Jul-Sep;43(3):177-184. doi: 10.47626/2237-6089-2021-0237. Epub 2021 Apr 21. PMID: 33890431; PMCID: PMC8638711. [cited 2022 July 22]
31. Sharpe PA, Williams HG, Granner ML, Hussey JR. A randomised study of the effects of massage therapy compared to guided relaxation on well-being and stress perception among older adults. Complement Ther Med. 2007 Sep;15(3):157-63. doi: 10.1016/j.ctim.2007.01.004. Epub 2007 Feb 20. PMID: 17709060. [cited 2022 July 22]
32. Shechter A, Kim EW, St-Onge MP, Westwood AJ. Blocking nocturnal blue light for insomnia: A randomized controlled trial. J Psychiatr Res. 2018 Jan;96:196-202. doi: 10.1016/j.jpsychires.2017.10.015. Epub 2017 Oct 21. PMID: 29101797; PMCID: PMC5703049. [cited 2022 July 22]
33. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013 May 17;8(5):e63773. doi: 10.1371/journal.pone.0063773. PMID: 23691095; PMCID: PMC3656905. [cited 2022 July 22]
34. Matsuoka Y, Hamazaki K. [Considering Mental Health from the Viewpoint of Diet: The Role and Possibilities of Nutritional Psychiatry]. Seishin Shinkeigaku Zasshi. 2016;118(12):880-894. Japanese. PMID: 30620820. [cited 2022 July 22]
35. Bilal M, Iqbal HMN. An insight into toxicity and human-health-related adverse consequences of cosmeceuticals – A review. Sci Total Environ. 2019 Jun 20;670:555-568. doi: 10.1016/j.scitotenv.2019.03.261. Epub 2019 Mar 20. PMID: 30909033. [cited 2022 July 22]
36. Ratnaseelan AM, Tsilioni I, Theoharides TC. Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes. Clin Ther. 2018 Jun;40(6):903-917. doi: 10.1016/j.clinthera.2018.05.004. Epub 2018 Jun 5. PMID: 29880330. [cited 2022 July 22]
37. Hardin BD, Kelman BJ, Saxon A. Adverse human health effects associated with molds in the indoor environment. J Occup Environ Med. 2003 May;45(5):470-8. doi: 10.1097/00043764-200305000-00006. PMID: 12762072. [cited 2022 July 22]